Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BY-NC-SA 4.0Journal of Clinical and Experimental Hematopathology : JCEH

Retained epcoritamab activity despite routine CD20 assay negativity approximately one terminal half-life after mosunetuzumab in B-cell lymphoma

  1. 1Department of Hematology, Yodogawa Christian Hospital, Osaka, Japan, Department of Artificial Intelligence and Digital Health Science, Kobe University Graduate School of Medicine, Kobe, Japan, Department of Pathology, Yodogawa Christian Hospital, Osaka, Japan

Abstract

CD20 testing shortly after CD20-directed therapy can be difficult to interpret. We report an 89-year-old woman with multiply relapsed B-cell lymphoma who underwent excisional biopsy of an enlarging right axillary lymph node 17 days after the last dose of mosunetuzumab. A prior lymph node biopsy showed follicular lymphoma grade 3A with preserved CD20 expression. The relapse specimen showed diffuse large B-cell lymphoma of the germinal center B-cell subtype. Immunohistochemistry using the CD20 clone L26 failed to detect CD20 expression, whereas PAX5 and CD79a remained positive. Flow cytometry showed undetectable CD20 with clone L27; the large-cell gate contained CD19-positive B cells and showed kappa light-chain restriction. No morphologic findings of a lineage switch were observed. IGH and IGK rearrangement analyses demonstrated identical monoclonal peaks in the specimens obtained at the follicular lymphoma stage and relapse, supporting clonal continuity. Positron emission tomography/computed tomography revealed a 40-mm right axillary lymph node with a maximum standardized uptake value of 26.7. Epcoritamab was started as the seventh-line treatment despite negativity on routine assays for CD20. During step-up dosing, grade 1 cytokine release syndrome resolved after one dose of tocilizumab. Computed tomography on day 22 revealed a reduction in the size of the right axillary lymph node from 40 to 20 mm. The lesion remained 20 mm on days 41 and 51, with decreases in lactate dehydrogenase and soluble interleukin-2 receptor. Disease progression was documented on day 83. These findings suggest that negative CD20 results by routine assays shortly after mosunetuzumab therapy do not necessarily reflect true target loss. Integrated interpretation of histopathology, flow cytometry, and clonality studies may help guide subsequent CD20-directed treatment decisions.

Related

  1. PTPN2/PTPN1 inhibition enhances ex vivo T- cell responses and potentiates mosunetuzumab activity in chronic lymphocytic leukemia
    Liron Yitzhak, Yamit Shorer Arbel, Yotam Bronstein +2
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textHuman geneticsCrossrefEurope PMC
  2. Real-world outcomes of mosunetuzumab use in relapsed/refractory indolent lymphomas: a CUBIC consortium analysis
    Andrew P. Jallouk, Lorenzo Falchi, Ayushi Chauhan +19
    Blood neoplasiaPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  3. FDA Approval Summary: Epcoritamab with Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma
    Rachel Ershler, Xueping Zhou, Keng Hee Peh +12
    Clinical cancer research : an official journal of the American Association for Cancer ResearchPeer-reviewedLicence not statedFull textGeneral medicinePMC
  4. Technical efficiency in hip arthroscopy plateaus after approximately 240 cases while complication rates continue to decline: A 15‐year single‐surgeon series of 1490 consecutive procedures
    Andrea Mei, Leonardo Clausetti, Martial Metrop +2
    Journal of experimental orthopaedicsPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
  5. Successful Treatment with Epcoritamab for Refractory Diffuse Large B-cell Lymphoma in a Dialysis-dependent Patient
    Yuya Sasaki, Keisuke Tanaka, Hisako Nakamaki +4
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
BibTeX
@article{kakiuchi2026retained,
  title = {{Retained epcoritamab activity despite routine CD20 assay negativity approximately one terminal half-life after mosunetuzumab in B-cell lymphoma}},
  author = {Seiji Kakiuchi and Hiroaki Akiyama and Naru Tomigaki and Akimasa Sakamoto and Shutaro Fujioka and Isamu Harima and Ryotaro Niwa and Ikumi Takagi and Yoko Kozuki and Yoshiharu Miyata and Nobuko Iwata and Kyoko Otani},
  journal = {Journal of Clinical and Experimental Hematopathology : JCEH},
  year = {2026},
  month = sep,
  doi = {10.3960/jslrt.26029},
  url = {https://doi.org/10.3960/jslrt.26029},
  note = {CC BY-NC-SA 4.0},
}
RIS
TY  - JOUR
TI  - Retained epcoritamab activity despite routine CD20 assay negativity approximately one terminal half-life after mosunetuzumab in B-cell lymphoma
AU  - Seiji Kakiuchi
AU  - Hiroaki Akiyama
AU  - Naru Tomigaki
AU  - Akimasa Sakamoto
AU  - Shutaro Fujioka
AU  - Isamu Harima
AU  - Ryotaro Niwa
AU  - Ikumi Takagi
AU  - Yoko Kozuki
AU  - Yoshiharu Miyata
AU  - Nobuko Iwata
AU  - Kyoko Otani
PY  - 2026
DA  - 2026/09/30
JO  - Journal of Clinical and Experimental Hematopathology : JCEH
DO  - 10.3960/jslrt.26029
UR  - https://doi.org/10.3960/jslrt.26029
AB  - CD20 testing shortly after CD20-directed therapy can be difficult to interpret. We report an 89-year-old woman with multiply relapsed B-cell lymphoma who underwent excisional biopsy of an enlarging right axillary lymph node 17 days after the last dose of mosunetuzumab. A prior lymph node biopsy showed follicular lymphoma grade 3A with preserved CD20 expression. The relapse specimen showed diffuse large B-cell lymphoma of the germinal center B-cell subtype. Immunohistochemistry using the CD20 clone L26 failed to detect CD20 expression, whereas PAX5 and CD79a remained positive. Flow cytometry showed undetectable CD20 with clone L27; the large-cell gate contained CD19-positive B cells and showed kappa light-chain restriction. No morphologic findings of a lineage switch were observed. IGH and IGK rearrangement analyses demonstrated identical monoclonal peaks in the specimens obtained at the follicular lymphoma stage and relapse, supporting clonal continuity. Positron emission tomography/computed tomography revealed a 40-mm right axillary lymph node with a maximum standardized uptake value of 26.7. Epcoritamab was started as the seventh-line treatment despite negativity on routine assays for CD20. During step-up dosing, grade 1 cytokine release syndrome resolved after one dose of tocilizumab. Computed tomography on day 22 revealed a reduction in the size of the right axillary lymph node from 40 to 20 mm. The lesion remained 20 mm on days 41 and 51, with decreases in lactate dehydrogenase and soluble interleukin-2 receptor. Disease progression was documented on day 83. These findings suggest that negative CD20 results by routine assays shortly after mosunetuzumab therapy do not necessarily reflect true target loss. Integrated interpretation of histopathology, flow cytometry, and clonality studies may help guide subsequent CD20-directed treatment decisions.
SN  - 1346-4280
SN  - 1880-9952
ER  -